CV Sciences (OTCMKTS:CVSI) and GLG Life Tech (OTCMKTS:GLGLF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.
This is a breakdown of current ratings and recommmendations for CV Sciences and GLG Life Tech, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|GLG Life Tech||0||0||0||0||N/A|
CV Sciences presently has a consensus target price of $8.50, indicating a potential upside of 114.73%. Given CV Sciences’ higher probable upside, equities analysts plainly believe CV Sciences is more favorable than GLG Life Tech.
Institutional and Insider Ownership
0.1% of CV Sciences shares are owned by institutional investors. 10.1% of CV Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares CV Sciences and GLG Life Tech’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CV Sciences||$48.24 million||8.22||$10.00 million||$0.09||43.98|
|GLG Life Tech||$14.95 million||0.56||-$12.98 million||N/A||N/A|
CV Sciences has higher revenue and earnings than GLG Life Tech.
This table compares CV Sciences and GLG Life Tech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|GLG Life Tech||-101.27%||N/A||-32.11%|
Volatility and Risk
CV Sciences has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500. Comparatively, GLG Life Tech has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.
CV Sciences beats GLG Life Tech on 9 of the 11 factors compared between the two stocks.
About CV Sciences
CV Sciences, Inc. operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape. This segment provides its hemp extract products in balms, sprays, drops, capsules, gummies, and softgel forms. It also sells raw materials to various customers that produce products for resale into the market in Europe. The Specialty Pharmaceuticals segment develops cannabinoids to treat a range of medical indications. Its product candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was founded in 2010 and is based in Las Vegas, Nevada.
About GLG Life Tech
GLG Life Tech Corp. engages in the production and supply of natural sweeteners. Its products include stevia extract and monk fruit which can be used in foods, dietary, supplements and cosmetic industry. The company was founded in 1999 and is headquartered in Richmond, Canada.
Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with MarketBeat.com's FREE daily email newsletter.